Medical Letter on the CDC & FDA

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

AIDS/HIV Vaccine

Vaccine provides T-cell-mediated protection in monkeys after SIV challenge

According to recent research from Italy, the Netherlands, Germany, and Sweden, "The immunogenicity and the protective efficacy of a new polyvalent triple vector (DNA/SFV/MVA)-based vaccine against mucosal challenge with pathogenic SIV_mac251 were investigated. Cynomolgus monkeys (Macaca fascicularis) were primed intradermally with DNA, boosted twice subcutaneously with recombinant Semliki Forest virus (rSFV) and finally intramuscularly with recombinant Modified Vaccinia Virus Ankara strain (rMVA). Both DNA and recombinant viral vectors...

• View Other Issues of Medical Letter on the CDC & FDA
  
• View Other NewsRx Publications